Medical Oncology

Papers
(The TQCC of Medical Oncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer44
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies44
The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer28
The role of inflammatory indices in the outcome of COVID-19 cancer patients27
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer27
COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients24
Can the host immune response against SARS-CoV2 also cause an anticancer effect?20
PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer20
Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer20
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China20
Identification of the role of mono-ADP-ribosylation in colorectal cancer by integrated transcriptome analysis19
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy18
Notch signaling in oral pre-cancer and oral cancer17
The “collateral damage” of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer17
Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells17
DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology16
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si16
Innovation in cancer therapeutics and regulatory perspectives15
ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells15
Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice14
sABLATE: a simplified ABLATE score for prediction of complications and outcome in percutaneous thermal ablation of renal lesions14
Levofloxacin might be safe to use for OSCC patients14
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies13
A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways13
AFP peptide (AFPep) as a potential growth factor for prostate cancer13
Combined evaluation of proliferation and apoptosis to calculate IC50 of VPA-induced PANC-1 cells and assessing its effect on the Wnt signaling pathway13
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model13
PARP1-modulated chromatin remodeling is a new target for cancer treatment13
Computational study on novel natural inhibitors targeting BCL213
Systematic identification of the cancer pathways and molecules related with breast cancer immunogenicity13
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells12
DNA methylation marker to estimate ovarian cancer cell fraction12
Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro12
Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?12
Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions12
In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma12
0.058759927749634